Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byActelion Pharmaceuticals
Price$250M
Date7/2013

General Information

Websiteceptaris.com
CategoryBioTech
Phone610-975-9290
Employees
Founded2002

Offices

Malvern, USA
101 Lindenwood Drive
Suite 400
Malvern, PA, 19355
USA

People

Vice President of Product Strategy
Vice President of Project Management and Operations
Vice President of Regulatory Affairs
Board of Directors
Board of Directors
Board of Directors
Board of Directors
Chairman and CEO
Show All People

Funding

Tags

Ceptaris Therapeutics

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris’ investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Recent Milestones

Videos

Screenshots

Ceptaris Therapeutics screenshot
Above: Home Page
Uploaded: 2/22/12

Sources

  1. Actelion to acquire Ceptaris Therapeutics for potentially upwards of $250 million (firstwordpharma.com) [edit]
  2. CEPTARIS SECURES $15M IN VENTURE DEBT FINANCING (ceptaris.com) [edit]
  3. Ceptaris Therapeutics Raises $10M in Series D-1 Funding (finsmes.com) [edit]
Edit This Page
Last Edited 12/8/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy